A novel cell-free screen identifies a potent inhibitor of the fanconi anemia pathway

International Journal of Cancer

Volumn 124, Issue 4, 2009, Pages 783-792

  Lanclais, Igor ^a   Sobeck, Alexandra ^a   Stone, Stacie ^a   LaChapelle, Alexis ^a   Hoatlin, Maureen E ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Chemosensitization; Cisplatin; DNA repair; Interstrand crosslinks

Indexed keywords

2,3 DICHLORO 5,8 DIHYDROXY 1,4 NAPHTHOQUINONE; ANTINEOPLASTIC AGENT; CISPLATIN; CURCUMIN; DNA; DOUBLE STRANDED DNA; FANCONI ANEMIA GROUP D2 PROTEIN; MRE11 PROTEIN; UNCLASSIFIED DRUG; WORTMANNIN; CROSS LINKING REAGENT; FANCD2 PROTEIN, HUMAN;

ARTICLE; CANCER RESISTANCE; CELL FREE SYSTEM; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SCREENING; EGG; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; UBIQUITINATION; XENOPUS; ANIMAL; BIOLOGICAL MODEL; CELL SURVIVAL; CHEMISTRY; DNA REPAIR; FANCONI ANEMIA; GENETICS; HELA CELL; INSTRUMENTATION; METABOLISM; METHODOLOGY; XENOPUS LAEVIS;

ANIMALS; CELL SURVIVAL; CELL-FREE SYSTEM; CISPLATIN; CROSS-LINKING REAGENTS; DNA; DNA DAMAGE; DNA REPAIR; DRUG EVALUATION, PRECLINICAL; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; HELA CELLS; HUMANS; MODELS, BIOLOGICAL; XENOPUS LAEVIS;

EID: 58149457080     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24039     Document Type: Article

References (43)

1. Musto P, D'Auria F. Melphaian: old and new uses of a still master drug for multiple myeloma. Expert Opin Invest Drugs 2007:16:1467-87.
2. Abu-Surrah AS, Kettunen M. Platinum group antitumor chemistry-design and development of new anticancer drugs complementary to cisplatin. Curr Med Chem 2006; 13:1337-57.
3. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006;5:952-61.
4. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
5. van der Groep P, Hoelzel M, Buerger H, Joenje H, de Winter JP, van Diest PJ. Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2008;107:41-7.
6. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD. Disruption of the Fanconi ane-mia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-74.
7. Tischkowitz M, Ameziane N, Waisfisz Q, De Winter JP, Harris R, Taniguchi T, D'Andrea AD, Hodgson SV, Mathew CG, Joenje H. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol 2003; 123:469-71.
8. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
9. Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, Moreau LA, Shimaraura A, D'Andrea AD. Fanconi anemia pathway-deficient tumor ceils are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007; 117:1440-9.
10. Sobeck A, Stone S, Costanzo V, de Graaf B, Reuter T, de Winter J, Wallisch M, Akkari Y, Olson S, Wang W, Joenje H, Christian JL, et al. Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks. Mol Cell Biol 2006;26:425-37.
11. Sobeck A, Stone S, Hoatlin ME. DNA structure-induced recruitment and activation of the Fanconi anemia pathway protein FANCD2. Mol Cell Biol 2007;27:4283-92.
12. Costanzo V, Gautier J. Xenopus cell-free extracts to study DNA damage checkpoints. Methods. Mol. Biol. 2004;241:255-67.
13. Costanzo V, Robertson K, Gander J. Xenopus cell-free extracts to study the DNA damage response. Methods Mol Biol 2004;280:213-27.
14. Murray AW. Cell cycle extracts. Methods Cell Biol 199i;36:581-605.
15. Tutter AV, Waiter JC. Chromosomal DNA replication in a soluble cell-free system derived from Xenopus eggs. Methods Mol Biol 2006;322:l21-37.
16. Niedernhofer LJ, Lalai AS, Hoeijmakers JH. Fanconi anemia (cross)-iinked to DNA repair. Cell 2005;l23:l191-8.
17. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grorape M, D'Andrea AD. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001:7:249-62.
18. Shimamura A, Montes de Oca R, Svenson JL, Haining N, Moreau LA, Nathan DG, D'Andrea AD. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 2002;100:4649-54.
19. Ham SW, Park J, Lee SJ, Kim W, Kang K, Choi KH. Naphthoquinone analogs as inactivators of cdc25 phosphatase. Bioorg Med Chem Lett 1998;8:2507-10.
20. Kim HJ, Mun JY, Chun YJ, Choi KH, Ham SW, Kim MY. Effects of a naphthoquinone analog on tumor growth and apoptosis induction. Arch Pharm Res 2003;26:405-10.
21. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001;298:865-72.
22. Costanzo V, Robertson K, Bibikova M, Kim E, Grieco D, Gottesman M, Carroll D, Gautier J. Mrell protein complex prevents double-strand break accumulation during chromosomal DNA replication.Moi Cell 2001 ;8:137-47.
23. Dupre A, Boyer-Chatenet L, Sattier RM, Modi AP, Lee JH, Nicolette ML, Kopelovich L, Jasin M, Baer R, Paull TT, Gautier J. A forward chemical genetic screen reveals an inhibitor of the Mrell-Rad50-Nbsl complex. Nat Chem Biol 2008:4:119-25.
24. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004: 18:1958-63.
25. Stone S, Sobeck A, van Kogelenberg M, de Graaf B, Joenje H, Christian J, Hoatlin ME. Identification, developmental expression and regulation of the Xenopus ortholog of human FANCG/XRCC9. Genes Cells 2007;12:841-51.
26. Howlett KG, Taniguchi T, Durkin SG, D'Andrea AD, Glover TW. The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum Mol Genet 2005; 14:693-701.
27. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD. S-phase-specific interaction of the Fanconi anemia protein. FANCD2. with. BRCA1 and. RAD51. Blood 2002:100: 2414-20.
28. Elledge SJ, Davis RW. Two genes differentially regulated in the cell cycle and by DNA-damaging agents encode alternative regulatory subunits of ribonucleotide reductase. Genes Dev 1990;4:740-51.
29. Gebhart GF. Comments on the isobole method for analysis of drug interactions. Pain 1992;51:381; author reply 83-8.
30. Pichierri P, Averbeck D, Rosselli F. DNA cross-link-dependent RAD50/MRE11/NBS1 subnuciear assembly requires the Fanconi anemia C protein. Hum Mol Genet 2002;11:2531-46.
31. Siddik ZH. Biochemical and molecular mechanisms of cisplatin resistance. Cancer Treat Res 2002; 112:263-84.
32. Meetei AR, Sechi S, Waliisch M, Yang D, Young MK, Joenje H, Hoatlin ME, Wang W. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol 2003;23:3417-26.
33. Taniguchi T, Garcia-Higuera I, Xu B, Andreassen PR, Gregory RC, Kim ST, Lane WS, Kastan MB, D'Andrea AD. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 2002;109:459-72.
34. Kim SM, Kumagai A, Lee J, Dunphy WG. Phosphorylation of Chkl by ATM- and Rad3-related (ATR) in Xenopus egg extracts requires binding of ATRIP to ATR but not the stable DNA-binding or coiled-coil domains of ATRIP. J Biol Chem 2005;280:38355-64.
35. Chang DJ, Lupardus PJ, Cimprich KA. Monoubiquitination of proliferating cell nuclear antigen induced by stalled replication requires uncoupling of DNA polymerase and mini-chromosome maintenance helicase activities. J Biol Chem 2006;281:32081-8.
36. Leach CA, Michael WM. Ubiquitin/SUMO modification of PCNA promotes replication fork progression in Xenopus iaevis egg extracts. J Cell Biol 2005; 171:947-54.
37. Tetef M, Margolin K, Ann C, Akraan S, Chow W, Coluzzi P, Leong L, Morgan RJ Jr, Raschko J, Shibata S, Somlo G, Doroshow JH. Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase IT trial. J Cancer Res Clin Oncol 1995;121:103-6.
38. Tetef M, Margolin K, Ahn C, Akman S, Chow W, Leong L, Morgan RJ Jr, Raschko J, Somlo G, Doroshow JH. Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Invest New Drugs 1995;13:157-62.
39. Verma R, Peters NR, D'Onofrio M, Tochtrop GP, Sakamoto KM, Varadan R, Zhang M, Coffino P, Fushman D, Deshaie RJ, King RW. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 2004;306:117-20.
40. Wignall SM, Gray NS, Chang YT, Juarez L, Jacob R, Burlingarae A, Schultz PG, Heald R. Tdentification of a novel protein regulating microtubule stability through a chemical approach. Chem Biol 2004;11:135-46.
41. Aquiles Sanchez J, Wonsey DR, Harris L, Morales J, Wangh LJ. Efficient plasmid DNA replication in Xenopus egg extracts does not depend on prior chromatin assembly. J Biol Chem 1995;270:29676-81.
42. Blow JJ, Laskey RA. Initiation of DNA replication in nuclei and purified DNA by a cell-free extract of Xenopus eggs. Ceil 1986;47:577-87.
43. Menut S, Lemaitre JM, Hair A, Mechali M. DNA Replication and chromatin assembly using Xenopus eggs or embryos advances in molecular biology: a comparative methods approach to the study of oocytes and embryos. Oxford: Oxford University press, 1999,196-226.